Search research articles
Contact Us
Filters
Showing results (131-140 of 181) with videos related to
Page
of 19
Sort By:
American Journal of Hematology
|
September 28, 2016
Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias
Brittany Knick Ragon, Hagop Kantarjian, Elias Jabbour, et al.
Frontiers in Oncology
|
October 16, 2018
Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia
Prajwal Boddu, Gautam Borthakur, Mythili Koneru, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
May 31, 2014
A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia
Alfonso Quintás-Cardama, Naval Daver, Hawk Kim, et al.
Blood
|
August 3, 2006
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia
Hagop Kantarjian, Yasuhiro Oki, Guillermo Garcia-Manero, et al.
American Journal of Hematology
|
November 28, 2017
Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression
Elias Jabbour, Johannes Düll, Musa Yilmaz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 14, 2018
Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia
Matthew S Davids, Michael Hallek, William Wierda, et al.
Blood
|
February 14, 2018
Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience
Susan O'Brien, Richard R Furman, Steven Coutre, et al.
American Journal of Hematology
|
June 25, 2017
Clinical characteristics and outcomes of previously untreated patients with adult onset T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma with hyper-CVAD based regimens
Preetesh Jain, Hagop Kantarjian, Nitin Jain, et al.
American Journal of Hematology
|
April 8, 2026
Recurrent Genomic Alterations in BCRi-Experienced CLL Patients Treated With Venetoclax: Extended Phase 2 Follow-Up
Jennifer A Woyach, Relja Popovic, Emily L Rossi, et al.
Leukemia & Lymphoma
|
August 7, 2020
Survivorship in AML - a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 years
Catherine Kendall Major, Hagop Kantarjian, Koji Sasaki, et al.
Page
of 19
Search research articles
Search
Showing results (131-140 of 181) with videos related to
Sort By:
Page
of 19
American Journal of Hematology
|
September 28, 2016
Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias
Brittany Knick Ragon, Hagop Kantarjian, Elias Jabbour, et al.
Frontiers in Oncology
|
October 16, 2018
Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia
Prajwal Boddu, Gautam Borthakur, Mythili Koneru, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
May 31, 2014
A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia
Alfonso Quintás-Cardama, Naval Daver, Hawk Kim, et al.
Blood
|
August 3, 2006
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia
Hagop Kantarjian, Yasuhiro Oki, Guillermo Garcia-Manero, et al.
American Journal of Hematology
|
November 28, 2017
Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression
Elias Jabbour, Johannes Düll, Musa Yilmaz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 14, 2018
Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia
Matthew S Davids, Michael Hallek, William Wierda, et al.
Blood
|
February 14, 2018
Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience
Susan O'Brien, Richard R Furman, Steven Coutre, et al.
American Journal of Hematology
|
June 25, 2017
Clinical characteristics and outcomes of previously untreated patients with adult onset T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma with hyper-CVAD based regimens
Preetesh Jain, Hagop Kantarjian, Nitin Jain, et al.
American Journal of Hematology
|
April 8, 2026
Recurrent Genomic Alterations in BCRi-Experienced CLL Patients Treated With Venetoclax: Extended Phase 2 Follow-Up
Jennifer A Woyach, Relja Popovic, Emily L Rossi, et al.
Leukemia & Lymphoma
|
August 7, 2020
Survivorship in AML - a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 years
Catherine Kendall Major, Hagop Kantarjian, Koji Sasaki, et al.
Page
of 19